News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 3, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Jul 28, 2022
Initial tranche supports the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and execution of Company's pipeline NEW YORK, July 28, 2022...
-
Jul 28, 2022
Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801) Expands pipeline to now include two clinical stage precision oncology candidates for...
-
Jun 1, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
May 26, 2022
Positive initial data support the potential of seribantumab to induce deep and durable benefit for patients with tumors harboring NRG1 fusions Clinical activity observed includes a 33% response...